MAZE THERAPEUTICS, INC. Earnings Per Share (Basic)
MAZE THERAPEUTICS, INC. (MAZE) reported Earnings Per Share (Basic) of -$0.76 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- MAZE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$0.76.
- MAZE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$0.45.
- MAZE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$0.65.
- MAZE THERAPEUTICS, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$0.66.
- MAZE THERAPEUTICS, INC. earnings per share, basic for fiscal 2025 was -$3.05, a 314.79% decline from fiscal 2024.
- MAZE THERAPEUTICS, INC. earnings per share, basic for fiscal 2024 was $1.42.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.76 10-Q · filed 2026-08-11 | -$1.22 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | -$0.45 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-03-25 | -$1.30 derived: net income ÷ weighted average shares · filed 2026-03-25 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$3.05 10-K · filed 2026-03-25 |
| 2025-09-30 | -$0.66 10-Q · filed 2025-11-06 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$2.45 10-Q · filed 2025-11-06 | -$3.36 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-06-30 | -$0.77 10-Q · filed 2026-08-11 | -$1.83 10-Q · filed 2026-08-11 | -$2.86 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$4.98 derived: net income ÷ weighted average shares · filed 2026-08-11 |
| 2025-03-31 | -$1.15 10-Q · filed 2026-05-12 | -$2.43 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$5.60 derived: net income ÷ weighted average shares · filed 2026-05-12 | -$5.39 derived: net income ÷ weighted average shares · filed 2026-05-12 |
| 2024-12-31 | -$2.02 derived: net income ÷ weighted average shares · filed 2026-03-25 | -$12.24 derived: net income ÷ weighted average shares · filed 2026-03-25 | -$6.43 derived: net income ÷ weighted average shares · filed 2026-03-25 | $1.42 10-K · filed 2026-03-25 |
| 2024-09-30 | -$10.25 10-Q · filed 2025-11-06 | -$4.42 derived: net income ÷ weighted average shares · filed 2025-11-06 | $3.49 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $5.92 10-Q · filed 2025-08-12 | $4.54 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | -$13.91 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |